Plain-English translation of NCT06620185 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers want to understand how your body's immune system reacts to two different ways of encountering the flu: through a live-attenuated influenza vaccine (LAIV) delivered as a nasal spray, or through direct exposure to live influenza A virus. This is basic science research designed to map out immune responses in the lungs and lymph tissues to help improve future flu vaccines and treatments.
Most flu vaccines are injected, but scientists believe that delivering vaccines through the nose might trigger stronger immunity in the respiratory tract—where flu actually enters your body. This study will help researchers understand whether this approach works better than current methods.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to either receive the nasal flu vaccine or be exposed to live flu virus in a controlled medical setting. You will have several clinic visits for tests (likely including blood samples and respiratory samples), medical monitoring, and follow-up assessments to measure how your immune system responds. The exact duration and number of visits will depend on your assigned group, but expect to be involved for several weeks.
AI-generated summary from trial data · Sep 11, 2026 · Not medical advice
United Kingdom
Sponsor
Imperial College London
Collaborators
Imperial College Healthcare NHS Trust
Enrollment target
~36 participants
Started
April 2025
Primary completion
July 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 55 Years
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Polly Fox, MSc
Imperial College London
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.